



## **IBA receives FDA clearance for its new Imaging Suite, a solid foundation for the development of future Image-Guided Proton Therapy (IGPT) solutions**

**IBA's adaPT Insight\* opens the way to increased proton therapy accuracy**

**Louvain-la-Neuve, Belgium November 27<sup>th</sup>, 2013 - IBA (Ion Beam Applications SA)**, the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its imaging software (I2C: FDA 510(k) K132847); based on a software platform developed in partnership with the University of Louvain (UCL). It enables imaging and correction capabilities for IBA's Proteus<sup>®</sup>ONE\*\* and Proteus<sup>®</sup>PLUS\*\*\* proton therapy systems, under the name adaPT Insight\*.

Being part of IBA's integrated proton therapy software suite, adaPT Treatment Suite, adaPT Insight\* incorporates image-guidance features such as 3D Cone Beam CT and stereoscopic X-Ray imaging for increased accuracy in patient treatments. It is fully integrated with major Oncology Information Systems and offers fast 6D corrections of patient positions. The modular architecture and workflow based approach builds a solid foundation for the development of future specific image-guided proton therapy solutions.

**Olivier Legrain, Chief Executive Officer of IBA commented:** "We are delighted to have received Marketing Authorization from the FDA for the adaPT Insight technology. The development of imaging capabilities is critical to the opening of treatments for new cancer indications in proton therapy and IBA has developed advanced radiation therapy solutions that improve the overall treatment experience for both clinicians and patients. adaPT Insight is just the latest technological advancement delivered by IBA as we maintain our unrivalled position as an innovator and the world's leader in the delivery of proton therapy."

**Beth Klein, VP Sales North America for IBA Proton Therapy added** "adaPT Insight answers a critical clinical need identified by our large installed base of users. Imaging during PT treatment offers a step function change for our users in terms of quality of care as well as expanded applications. This is another demonstration of IBA's continuing commitment to provide its customers with the most advanced tools available to deliver the highest quality proton therapy treatments."

**Frederic Genin, Executive VP Product Management at IBA added:** "It is the talent and determination of our teams at IBA and UCL that makes it possible to achieve this significant milestone in the development of specific imaging solutions for proton therapy. Specific applications of image-guidance and image-monitoring are of paramount importance to benefit from the proton therapy's



superior dose distribution. Thanks to our strong imaging group, successful collaborations with UCL and key users, we have built the foundation enabling the installation of proton therapy specific Cone Beam CT and paving the way to Adaptive Proton Therapy.”

*\*adaPT Insight is the brand name of the I2C software suite applicable to the IBA Proton Therapy solutions. (I2C: FDA 510(k) K132847);*

*\*\*Proteus®ONE is the brand name of a new configuration of the Proteus® 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

*\*\*\*Proteus®PLUS is the brand name of a configuration of the Proteus® 235.*

-ENDS-



## Notes to Editors

### About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumour, sparing healthy surrounding tissue. Higher doses can be delivered to the tumour without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide utilize IBA solutions. This includes 15 proton therapy centres in operation and 11 centres under development. Over 25,000 patients have been treated on IBA equipment – more than all competitor installations combined.

### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)



**For further information please contact:**

**IBA**

**Olivier de Sadeleer**

Marketing Manager, Proton Therapy

+32 10 475 890

[Communication@iba-group.com](mailto:Communication@iba-group.com)

**Thomas Ralet**

Vice-President Corporate Communication

+32 10 475 890

[communication@iba-group.com](mailto:communication@iba-group.com)

**For media and investor enquiries:**

**Consilium Strategic Communications**

Amber Bielecka, Mary-Jane Elliott, Matthew Neal

+44 (0) 207 920 2354

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)